Details

Autor(en) / Beteiligte

• Belenkov, Yu N
• Arutyunov, G P
• Mareev, V Yu
• Koziolova, N A
• Sitnikova, M Yu
• Ageev, F T
• Gilyarevsky, S R
• Chesnikova, A I
• Yakushin, S S
• Perepech, N B
• Mareev, Yu V

Titel

Prospects for use of Vericiguat in HFrEF: Implications of VICTORIA Trial Results. Advisory Board Summary

Ist Teil von

• Kardiologiia, 2023-05, Vol.63 (4), p.3-10

Ort / Verlag

Russia (Federation)

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In September 2021, an online meeting of the Council of Experts was held. The proposed focus of discussion was publishing the results of an international prospective, randomized, double-blind, placebo-controlled study VICTORIA. The objective of the VICTORIA study was evaluation of the efficacy and safety of supplementing a standard therapy with vericiguat at a target dose of 10 mg twice a day as compared to placebo for prevention of cardiovascular death and hospitalization for heart failure (HF) in patients with clinical manifestations of chronic HF and left ventricular ejection fraction <45% who have recently had an episode of decompensated HF. The aim of the meeting was interpretation of the VICTORIA study results on efficacy and safety of vericiguat for a potential use in a Russian population of patients after a recent episode of decompensated chronic HF with reduced ejection fraction.